Mankind Pharma Share Price
Mid Cap | Pharmaceuticals and health care | NSE: MANKIND | BSE: 543904
₹2,480.75 
43.80 (1.80 %)
Last Updated: 01 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 2,447.50
High (₹) 2,528.80
Low (₹) 2,439.00
Prev. Close (₹) 2,436.95
Volume 17,047
VWAP (₹) 2,444.55
ROCE (%) 24.56
Industry P/E 46.23
TTM P/E 50.14
P/B Ratio 10.38
Market Cap (₹) Cr.1,02,382.60
Dividend Yield (%)--
EPS (₹) 47.68
ROE19.95%
Sales Growth (%) 18.12
Profit Growth (%)48.51
Day Range
2,528.802,528.80
52 Week Range
1,910.103,050.00
Historical Returns
Returns (6M)
22.19 %
Returns (1Y)
20.6 %
Returns (3Y)
74.2 %
Returns (5Y)
74.2 %
Returns (6M)
22.19 %
Returns (1Y)
20.6 %
Returns (3Y)
74.2 %
Returns (5Y)
74.2 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (49.00%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Company with 49.00% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 48.81
MFI 45.75
ATR 115.49
Commodity Channel Index -93.50
ROC125 19.98
ROC21 -15.39
Williams %R -78.48
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 2,483.41 | 2,529.88 | 2,565.46 | 2,447.83 | 2,401.36 | 2,365.78 | 2,319.31 |
| Week Ago | 2,568.20 | 2,630.55 | 2,673.65 | 2,525.10 | 2,462.75 | 2,419.65 | 2,357.30 |
| Month Ago | 2,920.36 | 2,960.38 | 2,993.06 | 2,887.68 | 2,847.66 | 2,814.98 | 2,774.96 |
EMA & SMA
2480.75
Current Price
Bullish Moving Averages
4
Bearish Moving Averages
16
5 Day 2462.59
9 Day 2516.07
10 Day 2557.26
12 Day 2545.74
14 Day 2563.62
20 Day 2663.24
26 Day 2711.59
50 Day 2669.59
100 Day 2629.06
200 Day 2416.08
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BNP PARIBAS ARBITRAGE | block | Sell | 25 Jan, 2024 | ₹2,060.65 | 3,12,695 | BSE |
| SOCIETE GENERALE | block | Buy | 25 Jan, 2024 | ₹2,060.65 | 3,12,695 | BSE |
| MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND | block | Buy | 25 Jan, 2024 | ₹2,060.65 | 82,213 | BSE |
| BEIGE LIMITED | bulk | Sell | 12 Dec, 2023 | ₹1,832.43 | 1,44,10,132 | BSE |
| KOTAK FUNDSINDIA MIDCAP FUND | bulk | Buy | 12 Dec, 2023 | ₹1,832.30 | 20,29,246 | BSE |
| GRANDEUR PEAK EMERGING MARKETS OPPORTUNITIES FUND | block | Sell | 20 Oct, 2023 | ₹1,800.55 | 1,30,182 | BSE |
| GRANDEUR PEAK GLOBL TRUST GP EMERGING MARKETS OPPORTUNITIES FUND | block | Buy | 20 Oct, 2023 | ₹1,800.55 | 1,30,182 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 09 Feb, 2024 | Puja Juneja | Disposal | ₹2,107.350000176107806154615609 | 22,71,336 | BSE |
| 09 Feb, 2024 | Arjun Juneja | Disposal | ₹2,107.350000083294185066352148 | 24,01,128 | BSE |
| 09 Feb, 2024 | Sheetal Arora | Disposal | ₹2,107.350000275168265394288607 | 18,17,070 | BSE |
Corporate Actions
No corporate actions available.
Announcements
| Date | Source | Detail |
|---|---|---|
| 30 Jan, 2025 | NSE India | Mankind Pharma Limited has informed the Exchange about Transcript |
| 30 Jan, 2025 | BSE India | Investor Conference Call for Q3 & 9M FY25 - Transcript |
| 24 Jan, 2025 | NSE India | Investor Conference Call for Q3 & 9M FY25 Audio Recording |
| 24 Jan, 2025 | BSE India | Investor Conference Call for Q3 & 9M FY25 - Audio Recording |
| 24 Jan, 2025 | NSE India | Monitoring Agency Report |
| 24 Jan, 2025 | NSE India | Newspaper Publication of Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2024 |
| 24 Jan, 2025 | BSE India | Monitoring Agency Report |
| 23 Jan, 2025 | NSE India | Mankind Pharma Limited has informed the Exchange about Investor Presentation |
| 23 Jan, 2025 | BSE India | Investor Presentation for Q3FY25 |
| 23 Jan, 2025 | NSE India | Mankind Pharma Limited has informed the Exchange regarding a press release dated January 23, 2025, titled ""Press Release on Financial Results of the Company for the Q3FY25"". |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 14 Jan, 2025 | 23 Jan, 2025 |
| Quarterly Results | -- | 28 Oct, 2024 | 05 Nov, 2024 |
| Quarterly Results | -- | 19 Jul, 2024 | 31 Jul, 2024 |
| Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. | 26 May, 2024 | 15 May, 2024 |
| Quarterly Results | -- | 17 Jan, 2024 | 31 Jan, 2024 |
| Quarterly Results | -- | 12 Oct, 2023 | 31 Oct, 2023 |
| Quarterly Results | -- | 20 Jul, 2023 | 02 Aug, 2023 |
| Audited Results | -- | 24 May, 2023 | 30 May, 2023 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Mankind Pharma
Mankind Pharma is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1991PLC044843 and registration number is 044843. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 9264.81 Cr. and Equity Capital is Rs. 40.06 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1991
Managing Director
-- --
NSE Symbol
MANKIND
Mankind Pharma Management
| Name | Designation |
|---|---|
| Mr. Ramesh Juneja | Chairman & Wholetime Director |
| Mr. Rajeev Juneja | Vice Chairman & Mng.Director |
| Ms. Sheetal Arora | WholeTime Director & CEO |
| Mr. Satish Kumar Sharma | Whole Time Director |
| Mr. Vivek Kalra | Independent Director |
| Mr. Tilokchand Punamchand Ostwal | Independent Director |
| Mr. Surendra Lunia | Independent Director |
| Mr. Bharat Anand | Independent Director |
| Ms. Vijaya Sampath | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,742.20  ₹1,743.95(-0.10%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,618.55  ₹5,577.70(0.73%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,439.50 ₹1,479.40(-2.70%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,481.60 ₹2,435.40(1.90%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,204.95 ₹1,217.35(-1.02%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Mankind Pharma
What is the share price of Mankind Pharma?
The share price of Mankind Pharma on 01 Feb, 2025 is ₹ 2,480.75.
What is 52W high and 52W low share price of Mankind Pharma?
The highest and lowest 52W share prices of Mankind Pharma are ₹ 3050.000 and ₹ 1910.100
What is the market cap of Mankind Pharma?
The market capitalization of Mankind Pharma as of 01 Feb, 2025 is ₹ 1,02,382.60 Crores
What is the P/E ratio of Mankind Pharma?
The current P/E ratio of Mankind Pharma as of 01 Feb, 2025 is 46.23
What is the PB ratio of Mankind Pharma?
The PB ratio of Mankind Pharma as of 01 Feb, 2025 is 10.38
Top Gainers
948IHFL26I
IBHFL NCD186
₹845
₹705 (0.2%)
GREAVESCOT
Greaves
₹281.85
₹234.9 (0.2%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.2%)
CAPRO
Caprola.Chem
₹62.4
₹52 (0.2%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.1%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.1%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0%)